ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
25 announcements
Prism Medico and Pharmacy reported unaudited standalone results for the quarter ended September 30, 2026. Quarterly net profit was Rs.22.65 lakhs, versus a loss a year earlier.
Prism Medico and Pharmacy will hold a board meeting on November 5, 2026 to consider unaudited standalone half-yearly financial results for the period ended September 2026. The trading window closes from October 1 until November 7, 2026.
Prism Medico and Pharmacy intimated BSE and MSEI that its corporate website is updated and functional per Regulation 46. This is a routine compliance undertaking with no financial impact.
Prism Medico and Pharmacy Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI Regulation 31. This is a routine filing.
Prism Medico and Pharmacy Limited has informed that no interest, dividend, or principal is payable on non-convertible securities for the quarter ending December 31, 2026.
Prism Medico and Pharmacy Limited re-appointed Davender Singh as a Non-Executive Non-Independent Director. The company also updated its statutory and secretarial auditor appointments.
Prism Medico and Pharmacy held its 24th Annual General Meeting on September 19, 2026, to transact ordinary and special business, including various investment approvals.
Prism Medico and Pharmacy Limited has filed its Annual Report for the financial year 2025-2026 in accordance with Regulation 34 of SEBI LODR Regulations.
Prism Medico and Pharmacy Limited has scheduled its 24th Annual General Meeting for September 19, 2026, through video conferencing to transact ordinary and special business.
Prism Medico and Pharmacy's board approved the Director's Report and the 24th AGM notice for September 19, 2026. It also recommended auditor appointments and preferential issue object variation.
Prism Medico and Pharmacy Limited has scheduled a board meeting on August 24, 2026, to approve the Director's Report and convene the 24th AGM.
Prism Medico and Pharmacy Ltd reported a net loss of ₹0.1 Cr for Q1 FY27.
Prism Medico and Pharmacy Limited has scheduled a board meeting for August 12, 2026, to consider its standalone unaudited financial results for the quarter ended June 2026.
Prism Medico and Pharmacy Limited has submitted an undertaking confirming its website is updated and functional in compliance with SEBI Regulation 46.
Prism Medico and Pharmacy Ltd filed its investor complaints report for the quarter ended June 30, 2026. No complaints were received or pending.
Prism Medico and Pharmacy Ltd reported revenue from operations of ₹0.3 Cr (+200.0% YoY) and a net loss of ₹0.2 Cr for Q4 FY26.
Prism Medico and Pharmacy approved its FY26 audited financial results showing annual revenue of ₹2.44 Crore. The board confirmed an unmodified audit opinion for the period.
Prism Medico and Pharmacy scheduled a board meeting on May 28, 2026. Directors will consider audited standalone financial results for the quarter and year ended March 2026.
Prism Medico and Pharmacy approved the appointment of Mr. Harpreet Singh as internal auditor for FY 2025-2026. This move ensures continued regulatory and financial compliance.
Prism Medico and Pharmacy Limited allotted 75,00,000 equity shares and 50,00,000 convertible warrants on a preferential basis at ₹10 each. The total fund raise amounts to ₹12.5 Crore, following shareholder approval at an EGM held on March 20, 2026.
Prism Medico and Pharmacy Limited confirmed it is not classified as a 'large corporate entity' as of March 31, 2026. Consequently, the SEBI mandated debt disclosure framework for large corporates is not applicable to the company.
Prism Medico and Pharmacy Limited reported nil investor complaints for the quarter ended March 31, 2026. All categories, including pending, received, and disposed complaints, remained at zero. The filing complies with Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Prism Medico and Pharmacy Ltd's promoters have confirmed that no shares held by them were encumbered or pledged during the financial year ended March 31, 2026. This annual disclosure under SEBI SAST Regulations reinforces transparency regarding promoter shareholding and the absence of new liens on their equity stake.
Prism Medico and Pharmacy Ltd confirmed it has no outstanding non-convertible securities. Consequently, there were no interest, dividend, or principal payment obligations due for the quarter ending March 31, 2026. This filing is a routine regulatory compliance disclosure under SEBI LODR Regulations.
Prism Medico and Pharmacy Ltd reported net profit of ₹0 Cr for Q3 FY26.